The prevalence of KRAS missense mutations was much higher in patients with rectal cancer (21/35, ~60%) than in those with colon cancer (197/590, ~33%) (p = 2.9E − 03, Supplementary Fig. 4e). The gene discussed is KRAS; the disease is rectal cancer.